全身免疫炎症指数与介入联合索拉非尼治疗肝癌患者预后相关性  

Correlation between Systemic Immune Inflammation Index and Prognosis of TACE Combined with Sorafenib in Patients with Liver Cancer

作　　者：张涵 刘四斌[1] ZHANG Han;LIU Sibin(Department of Radiology,Jingzhou Hospital Affiliated to Yangtze University,Jingzhou,Hubei Province 434000,P.R.China)

机构地区：[1]长江大学附属荆州医院放射科,荆州434000 [2]青岛大学附属威海市中心医院放射科,威海264300

出　　处：《临床放射学杂志》2023年第2期317-321,共5页Journal of Clinical Radiology

摘　　要：目的探究全身免疫炎症指数(SII)与经导管肝动脉化疗栓塞(TACE)联合索拉非尼治疗中晚期肝癌(HCC)患者预后相关性。方法回顾性分析2018年12月至2020年12月威海市中心医院综合介入科收治的中晚期HCC患者45例,患者均接受TACE联合索拉非尼治疗,绘制受试者工作特征(ROC)曲线并计算SII最佳临界值,利用单因素、多因素回归分析、Kaplan-Meier生存曲线判断术前SII与患者生存期的相关性。结果SII与肿瘤大小、巴塞罗那肝癌临床分期(BCLC)具有相关性(P<0.05)。单因素及多因素分析显示:SII、肿瘤大小、BCLC分期与接受TACE联合索拉非尼治疗HCC患者总体生存率(OS)具有显著相关性(P<0.05),且为这类患者OS的独立危险因素。Kaplan-Meier生存分析显示:术前SII>317的患者行TACE联合索拉非尼治疗后预后较差。结论术前较高SII值(>317)与TACE联合治疗HCC患者不良预后相关,可作为TACE联合治疗患者的预后预测因子,更好地对患者进行分层和制定个性治疗计划。Objective To explore the correlation between systemic immune inflammation index(SII)and the prognosis of patients with advanced liver cancer treated by TACE combined with sorafenib.Methods 45 patients with advanced liver cancer treated in the comprehensive interventional Department of Weihai Central Hospital from January 2019 to January 2022 were analyzed retrospectively.All patients were treated with TACE combined with sorafenib.The receiver operating characteristic(ROC)curve was drawn and the best critical value of SII was calculated.The correlation between preoperative SII and patient survival was judged by univariate and multivariate regression analysis and Kaplan-Meier survival curve.Results SII was correlated with tumor size and BCLC stage(P<0.05).Univariate and multivariate analysis showed that SII,tumor size and BCLC stage were significantly correlated with OS in patients with liver cancer treated with TACE combined with sorafenib(P<0.05).Kaplan-Meier survival analysis showed that patients with preoperative SII>317 had poor prognosis after TACE combined with sorafenib.Conclusion higher preoperative SII value(>317)was associated with poor prognosis in patients with liver cancer treated with TACE,which can be used as a noninvasive,low-cost and powerful prognostic factor for patients treated with TACE.This inflammation/immune related marker can complement the current prognostic regimen to better stratify patients and develop personalized treatment plans.

关 键 词：全身免疫炎症指数 中晚期肝癌 中性粒细胞 淋巴细胞 血小板 索拉非尼 

分 类 号：R735.7[医药卫生—肿瘤]